
Quarterly ResultNov 13, 2026, 09:31 AM
Lifeward Q3 Revenue Down 12% to $5.4M; AlterG Revenue Up 18%
AI Summary
Lifeward Ltd. reported its third quarter 2026 financial results, with total revenue decreasing 12% year-over-year to $5.4 million. While AlterG revenue saw an 18% increase to $3.6 million, ReWalk exoskeleton revenue declined due to a transition to a channel-partner distribution model. The company experienced a decrease in gross margin and an increase in operating expenses, leading to a wider net loss of $5.1 million ($1.32 per share). Lifeward is advancing its transition of ReWalk to a capital-efficient model and focusing on AI-enabled rehabilitation technologies.
Key Highlights
- Lifeward Ltd. reported Q3 2026 revenue of $5.4 million, a 12% decrease year-over-year.
- AlterG revenue increased 18% year-over-year to $3.6 million in Q3 2026.
- ReWalk exoskeleton revenue decreased to $1.7 million from $3.0 million in Q3 2025 due to channel transition.
- Gross margin decreased to 27.4% in Q3 2026 from 43.7% in Q3 2025.
- Total operating expenses increased to $7.5 million in Q3 2026 from $5.9 million in Q3 2025.
- Net loss widened to $5.1 million ($1.32 per share) in Q3 2026 from $3.2 million ($2.37 per share) in Q3 2025.
- Unrestricted cash and cash equivalents were $4.5 million as of September 30, 2026.
Price Impact
More from LFWD